|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Pittsburgh |
|---|---|
| Collaborator: |
Abraxis BioScience Inc. |
| Information provided by: | University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT00177814 |
Purpose
The proposed endpoints of the study would be: comparative use of piperacillin versus broader spectrum agents (e.g., piperacillin/tazobactam, etc.) [measured as defined daily doses per 1000 patient days]; physician acceptance of piperacillin as part of a streamlining program [measured as successful occurrences of the use of piperacillin as streamlining therapy]; changes in susceptibility patterns of broad spectrum antibiotics [measured as % Gram negative bacilli susceptible to each of the commonly used broad spectrum antibiotics]; and outcome of patients treated with streamlined therapy.
| Condition |
|---|
|
Gram-Negative Bacterial Infections |
| Study Type: | Observational |
| Study Design: | Retrospective |
| Official Title: | Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit |
| Estimated Enrollment: | 1000 |
| Study Start Date: | September 2005 |
| Estimated Study Completion Date: | December 2012 |
The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, recent immunomodulative therapies, physical exam findings, laboratory and radiographical data, antimicrobial usage, microbiological data and resistance patterns, choice of antibiotics once organism is identified, suspected source of infection, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome, gender, height, weight, ethnicity, and past medical history.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
patients treated with piperacillin/tazobactam and or piperacillin
Inclusion Criteria:
Contacts and Locations| Contact: David Paterson, MD | 412-648-6401 | patersond@dom.pitt.edu |
| Contact: Diana Pakstis, RN, BSN | 412-648-6401 | pakstisdl@dom.pitt.edu |
| United States, Pennsylvania | |
| University of Pittsburgh Medical Center | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Contact: David Paterson, MD 412-648-6401 patersond@dom.pitt.edu | |
| Contact: Diana Pakstis, RN, BSN 412-648-6401 pakstisdl@dom.pitt.edu | |
| Principal Investigator: David Paterson, MD | |
| Principal Investigator: | David Paterson, MD | University of Pittsburgh |
More Information
| Responsible Party: | UPMC ( David Paterson, MD ) |
| Study ID Numbers: | IRB # 0508074 |
| Study First Received: | September 13, 2005 |
| Last Updated: | December 2, 2009 |
| ClinicalTrials.gov Identifier: | NCT00177814 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
pipercillin gram negative bacteria infections |
|
Bacterial Infections Anti-Infective Agents Anti-Bacterial Agents Therapeutic Uses |
Piperacillin Infection Pharmacologic Actions Gram-Negative Bacterial Infections |
